In a new report, the analysts at health care boutique Leerink highlight numerous upcoming catalysts for some top stocks in the sector. Catalysts may move the stocks sharply either way, depending on the outcomes.
ThinkstockShort sellers have many reasons to bet against a stock, some of which are hedging or part of a larger theme. Other reasons may be a bet against a company or sector, or in…
Here are the four top biotech names we found that all have hepatitis C drugs in their current pipelines at one stage or another and that could be the next takeover targets.
A new research note from Credit Suisse maintains that the top large cap biotech leaders are leading the comeback rally from the hard sell-off. Here are the top large cap biotech stocks to buy…
GW Pharmaceuticals was one of the stocks surging on Friday, on news that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation status to the company's Epidiolex.
Halozyme Therapeutics saw its stock surge on Thursday on news reports that the FDA has removed its clinical hold on patient enrollment and dosing of in the certain ongoing Phase 2 trials.
Here are four top medical device makers that the Leerink team thinks make sense as potential takeover candidates, but also have more than enough merit to stand on their own.
UnitedHealth Group must be doing OK. The largest health insurer has announced a dividend hike and a new share buyback plan.
A new research report from Cowen suggests that biotech investors appear to be looking forward to what they describe as a "return to normalcy" following the roller coaster ride of early 2014.
ThinkstockAs the summer starts, a large agenda is out there for investors when it comes to top biotech and specialty pharmaceutical companies making announcements and presenting clinical data. The biggest health care conference is…
ThinkstockCanada-based Valeant Pharmaceuticals Inc. (NYSE: VRX) has raised its offer for Allergan Inc. (NYSE: AGN) for the second time this week. The latest offer, announced just minutes ago includes $72 a share and 0.83…
ThinkstockThe United States is not alone as our population ages. We join Japan and several other developed nations with a larger percentage of the population growing older. Better diet, exercise and health care are…
Pfizer looks like it is out of the bid now for AstraZeneca. What looks increasingly obvious for a lackluster performance is that Pfizer may now simply be having an identity crisis.
BioCryst Pharmaceuticals broke higher Tuesday morning, following the company's announcement that its oral drug for hereditary angioedema met objectives established for its Phase 2a clinical trial.
A new research report from Cowen cautions that progress on a cure for pancreatic cancer is slow, but steady. Drugs from three companies though have been favorably viewed by consultants.